Literature DB >> 6822328

Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis.

M Shimizu, M Ohyama, Y Takahashi, K Udo, M Kojima, M Kametani, F Tsuda, E Takai, Y Miyakawa, M Mayumi.   

Abstract

We attempted to diagnose fulminant type B hepatitis by the hepatitis B core antibody of the immunoglobulin M class. Of 27 consecutive cases of fulminant hepatitis not due to drug-related causes or type A hepatitis, 11 cases with and 9 without hepatitis B surface antigen in the serum revealed a high activity of immunoglobulin M hepatitis B core antibody by radioimmunoassay (S/N ratio 36.3 +/- 20.3). The remaining 7 cases with presumed non-A, non-B hepatitis, as well as the other 4 cases with drug-related causes, did not show any detectable activity (0.99 +/- 0.16). Serums from 30 asymptomatic carriers did not reveal a high activity of immunoglobulin M hepatitis B core antibody (2.1 +/- 1.2), although titers of non-class-specific hepatitis B core antibody were invariably high. On the basis of the results obtained, immunoglobulin M hepatitis B core antibody may be applied for the diagnosis of type B etiology in cases of fulminant hepatitis with or without hepatitis B surface antigen in the serum.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822328

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Phosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibody.

Authors:  A Machida; H Ohnuma; F Tsuda; A Yoshikawa; Y Hoshi; T Tanaka; S Kishimoto; Y Akahane; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 2.  Serological responses to HBV infection.

Authors:  E A Fagan; R Williams
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

3.  Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels.

Authors:  Doan Y Dao; Linda S Hynan; He-Jun Yuan; Corron Sanders; Jody Balko; Nahid Attar; Anna S F Lok; R Ann Word; William M Lee
Journal:  Hepatology       Date:  2012-01-31       Impact factor: 17.425

4.  Post-transfusion hepatitis type B: long incubation period and poor prognosis in compromised hosts.

Authors:  K Inoue; T Konda; K Takashima; Y Kuwabara; H Sasaki
Journal:  Gastroenterol Jpn       Date:  1989-04

5.  Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases.

Authors:  S Takano; M Omata; M Ohto; Y Satomura
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

6.  IgM antibody against hepatitis B core antigen (IgM anti-HBc): diagnostic and prognostic significance in acute HBsAg positive hepatitis.

Authors:  C Lavarini; P Farci; E Chiaberge; V Veglio; D Giacobbi; G Bedarida; G Susani; M Toti; P Almi; N Caporaso
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-29

7.  Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections.

Authors:  W H Gerlich; A Uy; F Lambrecht; R Thomssen
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

8.  [Anti-HBc IgM in acute and chronic hepatitis B virus infection].

Authors:  K Gmelin; L Theilmann; G Hasche; H Will; P Czygan; H W Doerr; B Kommerell
Journal:  Klin Wochenschr       Date:  1984-09-03

9.  A case of HBs antigen negative fulminant hepatitis with IgM antibody to hepatitis B core antigen persisting more than seven years.

Authors:  M Suga; K Shibata; T Kodama; K Arima; S Yamada; A Yachi
Journal:  Gastroenterol Jpn       Date:  1991-10

10.  Significance of IgM antibody to hepatitis B core antigen for the differential diagnosis of acute and chronic hepatitis B virus infection and for the evaluation of the inflammatory activity of type B chronic liver diseases.

Authors:  K Kiyosawa; S Wada; Y Imai; T Sodeyama; E Tanaka; H Yoda; S Furuta; M Kameko; M Kanai
Journal:  Gastroenterol Jpn       Date:  1986-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.